tetano
Editor, Senior Moderator
Cell Rep Med
. 2024 Aug 23:101701.
doi: 10.1016/j.xcrm.2024.101701. Online ahead of print. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster
Qian Wang[SUP] 1 [/SUP], Ian A Mellis[SUP] 2 [/SUP], Yicheng Guo[SUP] 3 [/SUP], Carmen Gherasim[SUP] 4 [/SUP], Riccardo Valdez[SUP] 4 [/SUP], Aubree Gordon[SUP] 5 [/SUP], David D Ho[SUP] 6 [/SUP], Lihong Liu[SUP] 7 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies are substantially expanded 1 month after a shot of XBB.1.5 monovalent mRNA vaccine (XBB.1.5 MV) booster, but the durability of this response remains unknown. Here, we address this question by performing neutralization assays on four viral variants (D614G, BA.5, XBB.1.5, and JN.1) using sera from participants obtained at ∼1 month, ∼3 months, and ∼6 months post an XBB.1.5 MV booster. Our findings indicate that the resulting neutralizing antibody titers are robust and generally remain at stable levels for the study period, similar to those following XBB infection. Importantly, this durability of neutralizing antibody titers contrasts with the decline observed after a booster of the original monovalent or BA.5 bivalent mRNA vaccine. Our results are in line with the recent national data from the Centers for Disease Control and Prevention, showing that the efficacy against symptomatic SARS-CoV-2 infection is sustained for up to 4 months after an XBB.1.5 MV booster.
Keywords: COVID-19; Omicron subvariant JN.1; SARS-CoV-2; XBB.1.5 monovalent mRNA vaccine; antibody decay rate; neutralizing antibody responses.
. 2024 Aug 23:101701.
doi: 10.1016/j.xcrm.2024.101701. Online ahead of print. Robust SARS-CoV-2-neutralizing antibodies sustained through 6 months post XBB.1.5 mRNA vaccine booster
Qian Wang[SUP] 1 [/SUP], Ian A Mellis[SUP] 2 [/SUP], Yicheng Guo[SUP] 3 [/SUP], Carmen Gherasim[SUP] 4 [/SUP], Riccardo Valdez[SUP] 4 [/SUP], Aubree Gordon[SUP] 5 [/SUP], David D Ho[SUP] 6 [/SUP], Lihong Liu[SUP] 7 [/SUP]
Affiliations
- PMID: 39208800
- DOI: 10.1016/j.xcrm.2024.101701
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies are substantially expanded 1 month after a shot of XBB.1.5 monovalent mRNA vaccine (XBB.1.5 MV) booster, but the durability of this response remains unknown. Here, we address this question by performing neutralization assays on four viral variants (D614G, BA.5, XBB.1.5, and JN.1) using sera from participants obtained at ∼1 month, ∼3 months, and ∼6 months post an XBB.1.5 MV booster. Our findings indicate that the resulting neutralizing antibody titers are robust and generally remain at stable levels for the study period, similar to those following XBB infection. Importantly, this durability of neutralizing antibody titers contrasts with the decline observed after a booster of the original monovalent or BA.5 bivalent mRNA vaccine. Our results are in line with the recent national data from the Centers for Disease Control and Prevention, showing that the efficacy against symptomatic SARS-CoV-2 infection is sustained for up to 4 months after an XBB.1.5 MV booster.
Keywords: COVID-19; Omicron subvariant JN.1; SARS-CoV-2; XBB.1.5 monovalent mRNA vaccine; antibody decay rate; neutralizing antibody responses.